Heart Failure

After receiving approval for a similar indication in type 2 diabetics in late 2019, the FDA has approved dapagliflozin for reducing risk of CV death and hospitalization in patients with HFrEF.

The latest scientific statement from the AHA addresses cardiovascular considerations before, during, and after pregnancy.

Discussing recent data from GALACTIC-HF with John Teerlink, MD, Executive Committee Chair for both GALACTIC-HF and COSMIC-HF.

New research from Weill Cornell Medicine is revealing more about the impact of social determinants on 90-day mortality following heart failure hospitalization.

An analysis of 60,000-plus patients over 2 decades suggests consumption of olive oil could help reduce rate of CVD.

Investigators from Saint Louis University discuss a new comparison of 2 drug classes that could reduce the risk of adverse cardiovascular events.

A discussion with Paul W. Armstrong of the University of Alberta, on the pandemic's effect on common ICU conditions.